Star Therapeutics
Category: AI in Healthcare
A clinical-stage biotechnology company that discovers and develops best-in-class antibody therapies for rare diseases in hematology and immunology. Star Therapeutics was founded in 2018. The company is led by Adam Rosenthal. Based in South San Francisco, USA. Team size: 11-50. Total funding raised: ~$410M total (all rounds). Latest round: Series D ($125M, Sep 2025 led by Sanofi Ventures). Key investors include Viking Global Investors, Sanofi Ventures, Sofinnova Investments, Westlake Village BioPartners, RA Capital Management.
- Founded
- 2018
- Headquarters
- South San Francisco, USA
- Team size
- 11-50
- Total funding
- ~$410M total (all rounds)
Value proposition
Developing first-in-class, once-monthly subcutaneous antibody therapies to address unmet needs in rare diseases, offering a more convenient and effective treatment option compared to frequent infusions.
Products and solutions
VGA039: A first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD).
Unique value
Star Therapeutics operates as an innovation engine with a 'hub-and-spoke' model, creating a family of portfolio companies (like Vega Therapeutics) to focus on specific rare diseases. Their 'pipeline-in-a-product' strategy allows them to target multiple diseases with a single therapy.
Target customer
Patients with rare diseases, initially focusing on those with hematologic and immunologic disorders.
Industries served
Biotechnology, Pharmaceuticals, Healthcare
Technology advantage
The company's key advantage lies in its expertise in antibody innovation and its ability to internally generate first-in-class drug programs from early discovery. This allows for a de-risked and efficient approach to drug development.
How they differentiate
Star Therapeutics differentiates through its unique 'constellation' business model, creating multiple portfolio companies for different diseases. Its lead product, VGA039, is a first-in-class, once-monthly subcutaneous antibody therapy for von Willebrand disease, offering a potential improvement in convenience and mechanism over existing treatments.
Main competitors
Takeda, CSL Behring, Disc Medicine
Key partnerships
Information on key partnerships or collaborations is not publicly available.
Notable customers
Not applicable for a pre-commercial biotech company.
Major milestones
Secured over $300 million in total funding, including a $125 million Series D round., Advanced its lead asset, VGA039, a first-in-class antibody for von Willebrand disease (VWD), to a global Phase 2/3 clinical trial., Established a 'constellation' model by launching subsidiary companies like Vega Therapeutics.
Growth metrics
Not publicly available as it is a clinical-stage company.
Market positioning
Positioned as a clinical-stage biotechnology company focused on developing best-in-class antibody therapies for rare diseases, with an initial strong focus on hematology and bleeding disorders.
Geographic focus
Based in the USA, with a global focus for its clinical trials and future market entry, primarily targeting North America and Europe.
Patents and IP
Specific patent information is not publicly available.
About Adam Rosenthal
Founder & CEO at Star Therapeutics. Previously, he was a Principal at Third Rock Ventures, where he was involved in the formation of several new companies. He was also the Co-founder and CEO of True North Therapeutics, which was acquired by Bioverativ.
Official website: https://star-therapeutics.com/